Featured Research

from universities, journals, and other organizations

How immune system B-cells react to very different substances

Date:
October 8, 2010
Source:
Max-Planck-Gesellschaft
Summary:
In order to track down pathogens and render them harmless, the immune system must be able to recognize myriad different foreign substances and react to them. Scientists have discovered how the immune system's B-cells can be activated by numerous substances from our environment. The receptor molecules on the surface of the B-cells are only activated when the receptor subunits separate following the binding of foreign substances. These findings turn the previous understanding of how B-cell receptors are activated on its head and may contribute to the development of new vaccination strategies and treatments for B-cell tumors.

On resting B-cells, the B-cell receptor forms oligomers from several subunits. The receptors are inactive in this form. The binding of the receptor to a matching binding partner (antigen) results in the dissolution of this oligomer structure and activates the signalling chains in the cell interior (flashes).
Credit: Max Planck Institute of Immunobiology

In order to track down pathogens and render them harmless, the immune system must be able to recognize myriad different foreign substances and react to them.

Scientists at the Max Planck Institute of Immunobiology and the Centre for Biological Signalling Studies BIOSS at the University of Freiburg have discovered how the immune system's B-cells can be activated by numerous substances from our environment. The receptor molecules on the surface of the B-cells are only activated when the receptor subunits separate following the binding of foreign substances. These findings turn the previous understanding of how B-cell receptors are activated on its head and may contribute to the development of new vaccination strategies and treatments for B-cell tumours.

Many human diseases, like the increasing number of autoimmune diseases and B-cell tumours such as leukaemia and lymphoma, are triggered by overactive receptors on the surface of white blood cells known as B-lymphocytes or B-cells. Each B-cell has up to 120,000 B-cell receptors on its surface. The activation of these receptors causes the cell to form antibodies. The receptors work on the basis of the lock and key principle, whereby a receptor (the lock) can only be activated by a matching substance (key) and trigger an immune response. If millions of keys can open one lock, the question arises as to how this lock works and how we are protected against the continuing over-activity of our immune response.

Jianying Yang und Michael Reth have now found an answer to this mystery of immune system activation. Using methods from synthetic biology they recreated the mouse B-cell receptor in a fruit-fly cell. Unlike in the previous research carried out in this area, the focus of their attention was the receptor on resting B-cells, the non-activated cells. To their surprise they discovered that the receptor on resting B-cells consists of several different sub-units and forms oligomers. In this form, sectors of the receptors that play an important role in signal transmission are concealed. If a matching binding partner bonds to the receptor, the oligomers disintegrate and the individual sub-units can become active.

"The separation process is largely dependent on the structure of the binding partner. This explains why the B-cell receptor can be activated by thousands of different substances," explains Michael Reth from the Max Planck Institute of Immunobiology. The discovery that the sub-units of the B-cell receptors form ordered oligomer complexes also leads to the conclusion that the receptors on resting B-cells can only be activated under precisely defined conditions.

Accepted doctrine refuted

The new model for the activation of the receptor is at variance with the hitherto accepted scientific doctrine. Up to now it was believed that the receptors exist in an unordered form in the cell membrane and only aggregate when they make contact with a binding partner. "In contrast, our new model is based on the dissolution and not the formation of a particular receptor structure. This marks a turning point in immunology research and, possibly also, in the field of cell biology," stresses Michael Reth. It appears that other receptor molecules also form oligomers in a resting state which only become active when they disintegrate into subunits or change their conformation.


Story Source:

The above story is based on materials provided by Max-Planck-Gesellschaft. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jianying Yang, Michael Reth. Oligomeric organization of the B-cell antigen receptor on resting cells. Nature, 2010; 467 (7314): 465 DOI: 10.1038/nature09357

Cite This Page:

Max-Planck-Gesellschaft. "How immune system B-cells react to very different substances." ScienceDaily. ScienceDaily, 8 October 2010. <www.sciencedaily.com/releases/2010/10/101006094234.htm>.
Max-Planck-Gesellschaft. (2010, October 8). How immune system B-cells react to very different substances. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2010/10/101006094234.htm
Max-Planck-Gesellschaft. "How immune system B-cells react to very different substances." ScienceDaily. www.sciencedaily.com/releases/2010/10/101006094234.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins